The WFH Shared Decision Making Tool for hemophilia treatment provides a framework to guide PWH through the thought process regarding treatment goals and preferences, provides evidence-based and balanced education on expected outcomes by treatment class, and helps PWH navigate the complexities of current treatment options. The tool is available for use in English, with Spanish and French versions coming soon—and even more languages as we move forward. The WFH SDM Tool is a “living” tool, meaning its data and information will be updated on a regular basis.
A three-month public comment period will be open from August 1 to November 1, 2023. We encourage you to participate in this important process by completing a survey on the WFH SDM Tool. Take a few moments and let us know what you think!
For more information on the WFH SDM Tool, contact us at [email protected].
The WFH SDM Tool is supported by an educational grant from BioMarin Pharmaceutical Inc., CSL Behring, Novo Nordisk, Pfizer and Spark Therapeutics.